氨基糖苷类药物性聋的遗传易感性研究进展  

Progress in genetic susceptibility to aminoglycoside-induced deafness

作　　者：田雨鑫 陈正侬[1] TIAN Yuxin;CHEN Zhengnong

机构地区：[1]上海交通大学附属第六人民医院耳鼻咽喉头颈外科,上海交通大学耳鼻咽喉科研究所,上海市睡眠呼吸障碍疾病重点实验室,上海200233

出　　处：《临床耳鼻咽喉头颈外科杂志》2021年第4期375-379,共5页Journal of Clinical Otorhinolaryngology Head And Neck Surgery

基　　金：国家自然基金重点项目(No:81770998)。

摘　　要：迄今已有200多种药物被报道具有耳毒性[1],临床表现为不同程度的听觉或前庭损伤,对患者生活造成严重影响[2]。其中,氨基糖苷类抗生素(aminoglycoside antibiotics,AmAn)引起的听觉损伤已证实具有遗传易感性,但因其具有生产成本极低、对大多数感染有广谱疗效等优势,现今仍被广泛使用[3]。近几十年对氨基糖苷类药物性聋(aminoglycoside antibiotic-induced deafness,AAID)相关的遗传性基因突变进行了大量研究报道,旨在更好地预防和治疗AAID。Aminoglycoside antibiotics can cause irreversible hearing loss, but they are still widely used because of their low production cost and broad-spectrum effect on most infections. Although it has been studied for decades, the mechanism of aminoglycoside-induced deafness has not been fully elucidated. Since patients’ individual susceptibility to aminoglycoside-ototoxicity varies considerably, it is necessary to identify high-risk patients. This review summarizes the genetic mutations linked to aminoglycoside-induced deafness, in order to provide reference for further prevention and treatment of aminoglycoside-induced deafness.

关 键 词：药物性聋 氨基糖苷类 遗传 耳毒性 易感性 

分 类 号：R764.43[医药卫生—耳鼻咽喉科]